Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden.
Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, Lai A. Nguyen HT, et al. Among authors: ravelo a. Neurooncol Pract. 2019 Mar;6(2):103-111. doi: 10.1093/nop/npy021. Epub 2018 Sep 20. Neurooncol Pract. 2019. PMID: 31386050 Free PMC article.
Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma.
Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. Taphoorn MJ, et al. Among authors: ravelo a. J Clin Oncol. 2015 Jul 1;33(19):2166-75. doi: 10.1200/JCO.2014.60.3217. Epub 2015 May 26. J Clin Oncol. 2015. PMID: 26014298 Clinical Trial.
Fostering a High-Functioning Team in Cancer Care Using the 4R Oncology Model: Assessment in a Large Health System and a Blueprint for Other Institutions.
Liu R, Weldon CB, Linehan E, Gordon N, Abbe T, Hennings M, James H, Katzel J, Ng C, Tomita M, Velotta JB, Ossowski S, Sakoda LC, Sprague SL, Dowling A, Beringer K, Ravelo A, Yu E, Trosman JR. Liu R, et al. Among authors: ravelo a. JCO Oncol Pract. 2023 Jan;19(1):e125-e137. doi: 10.1200/OP.22.00287. Epub 2022 Sep 30. JCO Oncol Pract. 2023. PMID: 36178937 Free PMC article.
First-Line Treatment with Bevacizumab and Platinum Doublet Combination in Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Cohort Study in US Oncology Community Practices.
Lunacsek OE, Ravelo A, Coutinho AD, Hazard SJ, Green MR, Willey J, Eaddy M, Goertz HP. Lunacsek OE, et al. Among authors: ravelo a. Drugs Real World Outcomes. 2016 Sep;3(3):333-343. doi: 10.1007/s40801-016-0090-5. Drugs Real World Outcomes. 2016. PMID: 27747837 Free PMC article.
Comparison of survival and hospitalization rates between Medicare patients with advanced NSCLC treated with bevacizumab-carboplatin-paclitaxel and carboplatin-paclitaxel: a retrospective cohort study.
Langer C, Ravelo A, Hazard SJ, Guerin A, Ionescu-Ittu R, Latremouille-Viau D, Wu EQ, Ramalingam S. Langer C, et al. Among authors: ravelo a. Lung Cancer. 2014 Dec;86(3):350-7. doi: 10.1016/j.lungcan.2014.09.017. Epub 2014 Sep 30. Lung Cancer. 2014. PMID: 25439437
161 results